{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:20:07Z","timestamp":1787664007029,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Depemokimab is the first ultra\u2010long\u2010acting biologic with enhanced interleukin\u20105 (IL\u20105) binding affinity, high potency, and extended half\u2010life, enabling twice\u2010yearly dosing. Depemokimab has demonstrated efficacy and safety in patients with asthma and chronic rhinosinusitis with nasal polyps. These analyses aimed to characterize the pharmacokinetic\/pharmacodynamic (PK\/PD) profile of depemokimab. Data from three Phase I studies (NCT03287310\/NCT05140200\/NCT05602025) and four Phase III studies (SWIFT\u20101\/\u20102: NCT04719832\/NCT04718103; ANCHOR\u20101\/\u20102: NCT05274750\/NCT05281523) were used to develop a PK model for depemokimab and PK\/PD model for blood eosinophil count (BEC) reduction, a key biomarker of type 2 inflammation. Participants received subcutaneous depemokimab or placebo (one dose in Phase I [2\u2010300 mg in NCT03287310; 100 mg or 300 mg in NCT05140200\/NCT05602025] and two 100 mg doses in Phase III) and \u22651 post\u2010first\u2010dose PK\/PD (BEC) observation. PK analysis included 961 participants and PK\/PD analysis included 1324 participants. Predicted geometric mean half\u2010life was 47 days, with negligible accumulation in PK. Depemokimab 100 mg rapidly reduced BEC to &lt;25% of baseline, with a small increase observed at the end of the 26\u2010week dosing interval. No clinically relevant covariates were identified for either model. All participants had trough depemokimab concentrations above the half maximal effective concentration (EC\n                    <jats:sub>50<\/jats:sub>\n                    ) at the end of the dosing interval (90% above the EC\n                    <jats:sub>90<\/jats:sub>\n                    level). PK\/PD modeling showed that single\u2010dose depemokimab 100 mg provides durable BEC reduction throughout a 26\u2010week dosing interval, suggesting sustained suppression of IL\u20105 activity. These data support twice\u2010yearly recommended dosing for depemokimab 100\u00a0mg, with no dose adjustments required based on intrinsic or extrinsic factors.\n                  <\/jats:p>","DOI":"10.1002\/jcph.70187","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:08:32Z","timestamp":1785413312000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps"],"prefix":"10.1002","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1804-2703","authenticated-orcid":false,"given":"Anders","family":"Thorsted","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Modelling and Simulation GSK  Solna Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9na\u00efg","family":"Tanneau","sequence":"additional","affiliation":[{"name":"Pharmetheus AB  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lavalley\u2010Morelle","sequence":"additional","affiliation":[{"name":"Pharmetheus AB  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Follows","sequence":"additional","affiliation":[{"name":"Clinical Research Respiratory, Inflammation and Immunology Research Unit (RIIRU) GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loretta","family":"Jacques","sequence":"additional","affiliation":[{"name":"Clinical Research Respiratory, Inflammation and Immunology Research Unit (RIIRU) GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5977-2561","authenticated-orcid":false,"given":"Nicholas","family":"Bird","sequence":"additional","affiliation":[{"name":"Biostatistics GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1629-8468","authenticated-orcid":false,"given":"Philippe","family":"Gevaert","sequence":"additional","affiliation":[{"name":"Upper Airways Research Laboratory Department of Head and Skin Ghent University Ghent Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Pavord","sequence":"additional","affiliation":[{"name":"Oxford Respiratory NIHR Biomedical Research Centre Nuffield Department of Clinical Medicine University of Oxford  Oxford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Ribbing","sequence":"additional","affiliation":[{"name":"Pharmetheus AB  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anubha","family":"Gupta","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modelling and Simulation GSK  Stevenage UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Specialty Care GSK  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stein","family":"Schalkwijk","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Modelling and Simulation GSK  Amsterdam Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.16303"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/alr.22994"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.resinv.2025.01.003"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00197-7"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2406673"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e44247"},{"key":"e_1_2_11_8_1","unstructured":"GSK.NUCALA (mepolizumab). Highlights of prescribing information. Accessed April 30 2025.https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Nucala\/pdf\/NUCALA\u2010PI\u2010PIL\u2010IFU\u2010COMBINED.PDF"},{"key":"e_1_2_11_9_1","unstructured":"GSK.NUCALA (mepolizumab). Summary of product characteristics. Accessed April 25 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/nucala\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15002"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70183"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079"},{"key":"e_1_2_11_13_1","unstructured":"ClinicalTrials.gov.Study of GSK3511294 in Healthy Chinese Participants. Accessed April 23 2025.https:\/\/clinicaltrials.gov\/study\/NCT05140200"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1506"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12838"},{"key":"e_1_2_11_16_1","unstructured":"BauerRJ.NONMEM users guide. Introduction to NONMEM 7.5. Accessed May 2025.https:\/\/nmhelp.tingjieguo.com\/guides\/intro7.pdf"},{"key":"e_1_2_11_17_1","unstructured":"The R Foundation.The R project for statistical computing. Accessed June 30 2025.https:\/\/www.r\u2010project.org\/"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.29095"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mucimm.2024.03.005"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00935-2021"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(17)30125-X"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00097-7"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60988-X"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.08.037"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00874-2"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2021.06.038"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.5414\/CP202446"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2008.01885.x"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.02.031"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01874-2019"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/0004563215593561"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70187","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jcph.70187","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcph.70187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T12:32:57Z","timestamp":1787661177000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/jcph.70187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jcph.70187"],"URL":"https:\/\/doi.org\/10.1002\/jcph.70187","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"2025-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70187"}}